Evaluation of Inhaler Prescribing Trends in Hospitalized Patients With Suspected but Unconfirmed Chronic Obstructive Pulmonary Disease.

IF 1.5 Q4 PHARMACOLOGY & PHARMACY
Alexandra E Mihm, Alexandria J Wingler, Madison P Owen, Erica R Anderson
{"title":"Evaluation of Inhaler Prescribing Trends in Hospitalized Patients With Suspected but Unconfirmed Chronic Obstructive Pulmonary Disease.","authors":"Alexandra E Mihm, Alexandria J Wingler, Madison P Owen, Erica R Anderson","doi":"10.1177/87551225261454868","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends initial bronchodilator therapy over inhaled corticosteroids (ICS) for most patients. However, real-world prescribing often diverges. Management is further complicated in hospitalized patients with suspected but unconfirmed chronic obstructive pulmonary disease (COPD), where providers must decide on therapy initiation and outpatient follow-up.</p><p><strong>Objective: </strong>To describe inhaler prescribing in suspected but unconfirmed COPD upon hospital discharge.</p><p><strong>Methods: </strong>This was an institutional review board-approved retrospective cohort study of patients of ages 40 years or older with a smoking history of at least 10-pack years, but without a prior COPD diagnosis, who presented with a suspected COPD exacerbation or acute respiratory failure secondary to suspected COPD. The primary outcome was inhaler prescribing at discharge. Secondary outcomes included confirmed COPD diagnosis, guideline concordance, hospital readmission for a COPD exacerbation, and ICS-related adverse events within 180 days.</p><p><strong>Results: </strong>Of the 51 patients included in the study, 29 (56.9%) were prescribed new inhalers, with 15 (29.4%) prescribed ICS-containing regimens. Following discharge, 15 patients (29.4%) completed pulmonary function testing, with 8 (15.7%) receiving a COPD diagnosis. Guideline concordance could not be assessed due to absent documentation. Eight patients (15.7%) were readmitted with a COPD exacerbation, and 13 ICS-related adverse events were documented. Limitations include the sample size and retrospective study design.</p><p><strong>Conclusion: </strong>This study found a high frequency of initial ICS prescribing for suspected but unconfirmed COPD, as well as limited follow-up and diagnostic reassessment. These findings highlight the need for system-level interventions to optimize discharge prescribing and ensure timely follow-up.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261454868"},"PeriodicalIF":1.5000,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318829/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225261454868","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends initial bronchodilator therapy over inhaled corticosteroids (ICS) for most patients. However, real-world prescribing often diverges. Management is further complicated in hospitalized patients with suspected but unconfirmed chronic obstructive pulmonary disease (COPD), where providers must decide on therapy initiation and outpatient follow-up.

Objective: To describe inhaler prescribing in suspected but unconfirmed COPD upon hospital discharge.

Methods: This was an institutional review board-approved retrospective cohort study of patients of ages 40 years or older with a smoking history of at least 10-pack years, but without a prior COPD diagnosis, who presented with a suspected COPD exacerbation or acute respiratory failure secondary to suspected COPD. The primary outcome was inhaler prescribing at discharge. Secondary outcomes included confirmed COPD diagnosis, guideline concordance, hospital readmission for a COPD exacerbation, and ICS-related adverse events within 180 days.

Results: Of the 51 patients included in the study, 29 (56.9%) were prescribed new inhalers, with 15 (29.4%) prescribed ICS-containing regimens. Following discharge, 15 patients (29.4%) completed pulmonary function testing, with 8 (15.7%) receiving a COPD diagnosis. Guideline concordance could not be assessed due to absent documentation. Eight patients (15.7%) were readmitted with a COPD exacerbation, and 13 ICS-related adverse events were documented. Limitations include the sample size and retrospective study design.

Conclusion: This study found a high frequency of initial ICS prescribing for suspected but unconfirmed COPD, as well as limited follow-up and diagnostic reassessment. These findings highlight the need for system-level interventions to optimize discharge prescribing and ensure timely follow-up.

疑似但未确诊的慢性阻塞性肺疾病住院患者吸入器处方趋势的评估
背景:全球慢性阻塞性肺疾病倡议(GOLD)报告建议大多数患者初始支气管扩张剂治疗优于吸入皮质类固醇(ICS)。然而,现实世界的处方往往是不同的。疑似但未确诊的慢性阻塞性肺疾病(COPD)住院患者的管理更加复杂,提供者必须决定开始治疗和门诊随访。目的:描述疑似但未确诊的慢性阻塞性肺病患者出院时使用吸入器的情况。方法:这是一项机构审查委员会批准的回顾性队列研究,患者年龄在40岁或以上,吸烟史至少10年,但之前没有COPD诊断,表现为疑似COPD加重或继发于疑似COPD的急性呼吸衰竭。主要结局是出院时的吸入器处方。次要结局包括COPD确诊、指南一致性、COPD加重再入院、180天内ics相关不良事件。结果:在纳入研究的51例患者中,29例(56.9%)使用了新的吸入器,15例(29.4%)使用了含有ics的方案。出院后,15名患者(29.4%)完成了肺功能检查,其中8名(15.7%)接受了COPD诊断。由于缺乏文献,无法评估指南的一致性。8名患者(15.7%)因COPD加重再次入院,记录了13例ics相关不良事件。局限性包括样本量和回顾性研究设计。结论:本研究发现,对于疑似但未确诊的COPD患者,初始使用ICS处方的频率较高,且随访和诊断重新评估有限。这些发现突出了系统层面干预的必要性,以优化出院处方并确保及时随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书